Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 3, 1999, Pages 372-385

  Holmlund, Jon T ^a   Monia, Brett P ^a   Kwoh, T Jesse ^a   Dorr, F Andrew ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; ISIS 2503; ISIS 3521; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BLOOD COAGULATION DISORDERS; CLINICAL TRIALS, PHASE I; COMPLEMENT PATHWAY, ALTERNATIVE; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; DRUG INTERACTIONS; FATIGUE; FEASIBILITY STUDIES; FEMALE; FEVER; FORECASTING; GENE THERAPY; GENES, RAS; HUMANS; ISOENZYMES; LIVER; MACACA FASCICULARIS; MALE; MICE; NEOPLASM PROTEINS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PARTIAL THROMBOPLASTIN TIME; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTO-ONCOGENE PROTEINS C-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); SAFETY; THIONUCLEOTIDES; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033065009     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Nishizuka Y: The molecular heterogeneity of protein kinase C and its Implications for cellular regulation. Nature (1988) 334:661-665.
2. Basu A: The potential of protein kinase C as a target for anticancer treatment Pharmacol Ther (1993) 59:257-280.
3. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (1992) 258:607-614.
4. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y: Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem (1982) 257:7847-7851.
5. Blobe GC, Obeid LM, Hannun YA: Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev (1994) 13:411-431.
6. Yuspa SH: The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis. Cancer Res (1994) 54:1178-1189.
7. Hm genes are mediated by protein kinase C-α. Cancer Res (1994) 54:6413-6420.
8. Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, Parker PJ: MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest (1995) 95:1906-1915.
9. Henttu P, Vihko P: The protein kinase C activator, phorbol ester, elicits disparate functional responses in androgen-sensitive and androgen-independent human prostatic cancer cells. Biochem Biophys Res Commun (1998) 244:167-171.
10. Pertetti GP, Smeraldi C, Porro D, Piccinini F: Involvement of the alpha isoenzyme of protein kinase C in the growth inhibition induced by phorbol esters in MH1C1 hepatoma cells. Biochem Biophys Res Commun (1994) 205:1589-1594.
11. Adesina AM, Dooley N, Yong VW, Nalbantoglu J: Differential role for protein kinase C-mediated signaling In the proliferation of medulloblastoma cell lines. Int J Oncol (1998) 12:759-768.
12. O'Brien C, Vogel VG, Singletary SE, Ward NE: Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res (1989) 49:3215-3217.
13. Daum G, Eisenmann-Tappe I, Fries H-W, Troppmair J, Rapp UR: The ins and outs of Raf kinases. Trends Biochem Sci (1994) 19:474-480.
14. Skolnik EY, Batzer A, Li N, Lee C-H, Lowenstein E, Mohammadi M, Margolis B, Schlessinger J: The function of GRB2 in linking the Insulin receptor to Ras signaling pathways. Science (1993) 260:1953-1955.
15. Fu H, Xia K, Pallas DC, Cui C, Conroy K, Narsimhan RP, Mamon H, Collier RJ, Roberts TM: Interaction of the protein kinase Raf-1 with 14-3-3 proteins. Science (1994) 266:126-129.
16. Crews CM, Alessandrini A, Erikson RL: The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science (1992) 258:478-480.
17. ras proteins bind to the animoterminal domain of C-Raf-1. Nature (1993) 364:308-313.
18. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res (1989) 49:4682-4689.
19. Rapp UR, Cleveland JL, Bonner TI, Storm SM: The raf oncogenes. In: The Oncogene Handbook. Reddy EP, Skalka AM, Curran T (Eds), Elsevier Science Publishers BV, Amsterdam (1988):213.
20. Stanton VP Jr, Cooper GM: Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol Cell Biol (1987) 7:1171-1179.
21. McCormick F: ras-related proteins in signal transduction and growth control. Mol Reprod Dev (1995) 42:500-506.
22. Hall A: The cellular functions of small GTP-binding proteins. Science (1990) 249:635-640.
23. Bokoch GM, Der CJ: Emerging concepts in the ras superfamily of GTP-binding proteins. FASEB J (1993) 7:750.
24. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A: The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell (1992) 70:401-410.
25. Liu AX, Testa JR, Hamilton TC, Jove R, Nicosia SV, Cheng JQ: AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinosltol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 58:2973-2977.
26. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, Wigler MH: Multiple ras functions can contribute to mammalian cell transformation. Cell (1995) 80:533-541.
27. Joneson T, White MA, Wigler MH, Bar Sagi D: Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science (1996) 271:810-812.
28. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell (1997) 89:457-467.
29. Van J, Roy S, Apolloni A, Lane A, Hancock JF: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem (1998) 273:24052-24056.
30. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR: Increased prevalence of K-ras oncogene mutations in lung adenocarclnoma. Cancer Res( 1995) 55:1444-1447.
31. Andreyev J, Norman A, Cunningham D, Dates J, Clarke P: Ki-ras mutations in 2,667 patients with colorectal cancer: RASCAL collaboration. Proc Am Soc Clin Oncol (1997) 16:257a.
32. Miyakis S, Sourvinos G, Spandidos DA: Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun (1998) 251:609-612.
33. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707-712.
34. Marcusson EG, Bhat B, Manoharan M, Bennett CF, Dean NM: Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res (1998) 26:2016-2023. Documentation that the use of cationic lipids does not prevent nuclear localization of phosphorothioate oligonucleotides.
35. Monia BP: First-and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anticancer Drug Des (1997) 12:327-339. Documents the selective inhibition of C-Raf mRNA in cell culture and animals.
36. Dean NM, McKay R, Condon TP, Bennett CF: Inhibition of protein kinase C-alpha expression In human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem (1994) 269:16416-16424. Demonstrates the selectivity of a phosphorothioate for PKC-α reduction without affecting other isoforms of PKC.
37. Dean NM, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M, Fabbro D: Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res (1996) 56:3499-3507.
38. Monia BP, Johnston JF, Ecker DJ, Zounes MA, Lima WF, Freier SM: Selective Inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem (1992) 267:19954-19962.
39. Monia BP: Disruption of the MAP kinase signaling pathway using antisense oligonucleotide inhibitors targeted to ras and raf kinase. In: Applied Antisense Oligonucleotide Technology. Stein CA, Krieg AM (Eds), John Wiley and Sons Inc. New York (1998):245-261.
40. Chen G, Oh S, Monia BP, Stacey DW: Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem (1996) 271:28259-28265.
41. Cowsert LM: In vitro and in vivo activity of antisense inhibitors of ras: potential for clinical development. Anticancer Drug Des (1997) 12:359-371.
42. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense Inhibitors of gene expression. J Biol Chem (1993) 268:14514-14522.
43. Monia BP, Johnston JF, Sasmor H, Cummins LL: Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J Biol Chem (1996) 271:14533-14540. Illustrates the effects of chemical modifications on oligonucleotide activity.
44. Dean NM, McKay R: Inhibition of protein kinase C-• expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA (1994) 91:11762-11766. Documents the reduction of PKC-α in animal tissues after oligonucleotide administration in vivo.
45. Johnston JF, Lu T, Cooper S, Trent K, Monia BP: Suppression of c-raf mRNA expression In mouse liver using 2′-O-methoxyethyl antisense oligonucleotides. Submitted (1999).
46. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol Pharmacol (1996) 50:236-242. Extensive human tumor xenograft study with documentation the of activity and quantitation of oligonucleotide levels in tumor tissue.
47. Leeds JM, Graham MJ, Truong L, Cummins LL: Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem (1996) 235:36-43. Describes CGE method of quantitating oligonucleotides in animal/clinical specimens.
48. Henry SP, Taylor J, Midgley L, Levin AA, Kombrust DJ: Evaluation of the toxicity of ISIS 2302, a phosporthioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev (1997) 7:473-481.
49. Henry SP, Monteith D, Bennett F, Levin AA: Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C-raf kinase. Anticancer Drug Des (1997) 12:409-420.
50. Henry SP, Grillone LR, Orr JL, Bruner RH, Kombrust DJ: Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothloate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology (1997) 116:77-88.
51. Henry SP, Monteith D, Levin AA: Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des (1997) 12:395-408. Excellent review of toxicology of this class of agent.
52. Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA: Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des (1997) 12:383-393. Review ofpreclinical pharmacokinetic data of AS ONs.
53. Henry SP, Giclas PC, Leeds J, Pangbum M, Auletta C, Levin AA, Kombrust DJ: Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J Pharmacol Exp Ther (1997) 281:810-816. Describes investigations into this effect of phosphorothioates.
54. Galbraith WM, Hobson WC, Giclas PC, Schlechter PJ, Agrawal S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev (1994) 4:201-206.
55. Plenat F, Klein-Monhoven N, Marie B, Vignaud J-M, Duprez A: Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistological, and direct fluorescence microscopy study. Am J Pathol (1995) 147:124-135.
56. Oberbauer R, Schreiner GF, Meyer TW: Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int (1995) 48:1226-1232.
57. Sarmiento UM, Perez JR, Becker JM. Narayanan R: In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev (1994) 4:99-107.
58. Monteith DK, Henry SP, Howard RB, Floumoy S, Levin AA, Bennett CF, Crooke ST: Immune stimulation - a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des (1997) 12:421-432.
59. Krieg AM, Yi A-K, Maison S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549.
60. Boggs RT, McGraw K, Condon T, Floumoy S, Villiet P, Bennett CF, Monia BP: Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev (1997) 7:461-471.
61. Levin AA. Monteith DK, Leeds JM, Nicklin PL, Geary RS, Butler M, Templin MV, Henry SP: Toxicity of oligodeoxynucleotide therapeutic agents. In: Handbook of Experimental Pharmacology, volume 131: Antisense Research and Application. Crooke ST (Ed), Springer-Verlag, Berlin (1998):169-215.
62. Butler M, Stecker K, Bennett CF: Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest (1997) 77:379-388. Important demonstration of distribution of phosphorothioates after iv administration.
63. Nestle FO, Mitra RS, Bennett CF, Chan H, Nickoloff BJ: Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phoshorothloate antisense oligonucleotides in keratinocytes. J Invest Dermatol (1994) 103:569-575.
64. Noonberg SB, Garavoy MR, Hunt CA: Characteristics of oligonucleotide uptake in human keratinocyte cultures. J Invest Dermatol (1993) 101:727-731.
65. Wu-Pong S, Weiss TL, Hunt CA: Calcium dependent cellular uptake of a c-myc antisense oligonucleotide. Cell Mol Biol (1994) 40:843-850.
66. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest (1995) 95:1814-1823.
67. Nemunaitis J, Von Hoff DD, Holmlund J, Dorr A, Eckhardt SG: Phase l/pharmacokinetic trial of a protein kinase C-α antisense oligonucleotide, ISIS 3521 (CGP 6412SA), administered twice weekly. Proc Am Soc Clin Oncol (1998) 17:211a, Abs812. Initial abstract report of first trial of ISIS-3521 in man.
68. Sheehan JP, Lan H-C: Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood (1998) 92:1617-1625.
69. Stevenson JP, Yao K-S, Gallagher M, Freidland D, Mitchell EP, Cassella A, Monia B, Yu R, Holmlund J, Dorr FA, O'Dwyer PJ: Phase I clinical/pharmacokinetic and pharmacodynamlc trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol (1999) in press. Report of first phase I trial of ISIS-5132.
70. Sikic BI, Yuen AR, Advani R, Halsey J, Fisher GA, Holmlund J, Dorr A: Antisense oligonucleotide therapy targeted to protein kinase C-α (ISIS 3521/CGP 64128A) by 21-day infusion: results of the phase I trial and activity In ovarian carcinomas. Proc Am Soc Clin Oncol (1998) 17:429a, Abs1654. Abstract describing toxcity and antitumor activity with a 21-day schedule.
71. Holmlund J, Nemunaitis J, Schiller J, Dorr A, Kisner D: Phase I trial of C-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc Am Soc Clin Oncol (1998) 17:210a, Abs811.
72. Dorr FA, Bruce J, Monia B, Johnston J, Geary R, Kwoh TJ, Holmlund J, Nemunaitis J: Phase I and pharmacokinetic trial of ISIS 2503, a 20-mer antisense oligonucleotide against H-ras, by 14-day continuous infusion (CIV) in patients with advanced cancer. Proc Am Soc Clin Oncol (1999) 18:Abs603. Abstract report of first trial with ISIS-2503.
73. Advani R, Fisher GA, Grant P, Yuen A, Holmlund JT, Kwoh TJ, Dorr, A, Geary B, Sikic BI: A Phase I trial of an antisense oligonucleotide targeted to protein kinase C-α (ISIS 3521/ISI 641A) delivered as a 24 hr. continuous infusion (Cl). Proc Am Soc Clin Oncol (1999) 18:Abs609.
74. Holmlund JT, Rudin CM, Mani S, Reming GF, Stadler W, Kunkel K, Kwoh TJ, Geary R, Dorr A, Ratain MJ: Phase I trial of ISIS 5132/ODN 698A, a 20-mer phosphorothloate antisense oligonucleotide inhibitor of C-raf kinase, administered by a 24-hour weekly intravenous IV infusion to patients with advanced cancer. Proc Am Soc Clin Oncol (1999) 18:Abs605.
75. Gordon MS, Sandler AB, Holmlund JT, Dorr A, Battiato L, Fife K, Geary R, Kwoh TJ, Sledge GW Jr: A Phase I trial of ISIS 2503, an antisense inhibitor of H-ras, administered by a 24-hour (HR) weekly infusion to patients (PTS) with advanced cancer. Proc Am Soc Clin Oncol (1999) 18:Abs604.
76. Sikic B, Yuen A, Advani R, Fisher G, Halsey J, Geary R, Kwoh TJ, Holmlund J, Dorr A: A Phase I trial of ISIS 3521 (ISI 641A), an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with cancer. Proc Am Soc Clin Oncol (1999) 18:Abs1718. First report of initial trial of ISIS-3521 + chemotherapy.
77. Mani S, Shulman K, Kunkel K, Geary R, Holmlund JT, Kwoh TJ, Dorr A, Rudin CM, Ratain MJ: Phase I trial of protein kinase C-a antisense oligonucleotide (ISIS 3521/ISI 641A) with 5-fluorouracil (5-FU) and leucovorin (LV) In patients with advanced cancer. Proc Am Soc Clin Oncol (1999) 18:Abs608.
78. O'Dwyer PJ, Stevenson JP, Gallagher M, Milchel E, Friedland D, Rose L, Cassella A, Holmlund J, Dean N, Dorr A, Geary R, Yao K-S: Phase l/pharmacokinetic/pharmacodynamic trial of Raf-1 antisense ODN (ISIS 5132, CGP 69846A). Proc Am Soc Clin Oncol (1998) 17:210a, Abs810.
79. Dean NM, Griffey RH: Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev (1997) 7:229-233.
80. McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM: Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J Biol Chem (1999) 274:1715-1722.